DDInter1035 DDInter1435
Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenalidomide is much safer and potent than thalidomide, with fewer adverse effects and toxicities.[A714, A228543] Thalidomide and its analogues, including lenalidomide, are referred to as immunomodulatory imide drugs (also known as cereblon modulators), which are a class of immunomodulatory drugs that contain an imide group. Lenalidomide works through various mechanisms of actions that promote malignant cell death and enhance host immunity
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Lenalidomide {u} (Compound) resembles {v} (Compound) Thalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Lenalidomide {u} (Compound) treats {v} (Disease) hematologic cancer
Lenalidomide {u} (Compound) binds {v} (Gene) PTGS2
Lenalidomide {u} (Compound) upregulates {v} (Gene) RRP8
Lenalidomide {u} (Compound) downregulates {v} (Gene) GDF15
Lenalidomide {u} (Compound) causes {v} (Side Effect) Cholecystitis
Lenalidomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Lenalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Lenalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chloramphenicol
Lenalidomide (Compound) resembles Thalidomide (Compound)
Lenalidomide (Compound) resembles Pomalidomide (Compound)
Lenalidomide (Compound) treats hematologic cancer (Disease)
Lenalidomide (Compound) binds PTGS2 (Gene)
Lenalidomide (Compound) upregulates RRP8 (Gene)
Lenalidomide (Compound) downregulates GDF15 (Gene)
Lenalidomide (Compound) causes Cholecystitis (Side Effect)
Lenalidomide may cause a minor interaction that can limit clinical effects when taken with Warfarin
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol